Blood–brainbarrier disruption dictates nanoparticle accumulation following experimental brain injury

Vimala N. Bharadwaj, Rachel K. Rowe, Jordan Harrison, Chen Wu, Trent R. Anderson, Jonathan Lifshitz, P. David Adelson, Vikram Kodibagkar, Sarah Stabenfeldt

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Clinically, traumatic brain injury (TBI) results in complex heterogeneous pathology that cannot be recapitulated in single pre-clinical animal model. Therefore, we focused on evaluating utility of nanoparticle (NP)-based therapeutics following three diffuse-TBI models: mildclosed-head injury (mCHI), repetitive-mCHI and midline-fluid percussion injury (FPI). We hypothesized that NP accumulation after diffuse TBI correlates directly with blood–brainbarrier permeability. Mice received PEGylated-NP cocktail (20-500 nm) (intravenously) after single- or repetitive-(1 impact/day, 5 consecutive days) CHI (immediately) and midline-FPI (1 h, 3 h and 6 h). NPs circulated for 1 h before perfusion/brain extraction. NP accumulation was analyzed using fluorescent microscopy in brain regions vulnerable to neuropathology. Minimal/no NP accumulation after mCHI/RmCHI was observed. In contrast, midlineFPI resulted in significant peak accumulation of up to 500 nm NP at 3 h post-injury compared to sham, 1 h, and 6 h groups in the cortex. Therefore, our study provides the groundwork for feasibility of NP-delivery based on NPinjection time and NPsize after mCHI/RmCHI and midline-FPI.

Original languageEnglish (US)
Pages (from-to)2155-2166
Number of pages12
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume14
Issue number7
DOIs
StatePublished - Oct 1 2018

Fingerprint

Nanoparticles
Brain Injuries
Brain
Percussion
Craniocerebral Trauma
Wounds and Injuries
Fluids
Brain models
Pathology
Microscopy
Permeability
Microscopic examination
Animals
Animal Models
Perfusion
Traumatic Brain Injury

Keywords

  • Blood-brain barrier
  • Drug delivery
  • Fluid percussion injury
  • Mild closed head injury
  • Nanoparticles
  • Optimal therapeutic window
  • Pharmacodynamics
  • Traumatic brain injury

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Molecular Medicine
  • Biomedical Engineering
  • Materials Science(all)
  • Pharmaceutical Science

Cite this

Blood–brainbarrier disruption dictates nanoparticle accumulation following experimental brain injury. / Bharadwaj, Vimala N.; Rowe, Rachel K.; Harrison, Jordan; Wu, Chen; Anderson, Trent R.; Lifshitz, Jonathan; Adelson, P. David; Kodibagkar, Vikram; Stabenfeldt, Sarah.

In: Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 14, No. 7, 01.10.2018, p. 2155-2166.

Research output: Contribution to journalArticle

Bharadwaj, Vimala N. ; Rowe, Rachel K. ; Harrison, Jordan ; Wu, Chen ; Anderson, Trent R. ; Lifshitz, Jonathan ; Adelson, P. David ; Kodibagkar, Vikram ; Stabenfeldt, Sarah. / Blood–brainbarrier disruption dictates nanoparticle accumulation following experimental brain injury. In: Nanomedicine: Nanotechnology, Biology, and Medicine. 2018 ; Vol. 14, No. 7. pp. 2155-2166.
@article{8f7ab928d1404a6f8946fc64605104d2,
title = "Blood–brainbarrier disruption dictates nanoparticle accumulation following experimental brain injury",
abstract = "Clinically, traumatic brain injury (TBI) results in complex heterogeneous pathology that cannot be recapitulated in single pre-clinical animal model. Therefore, we focused on evaluating utility of nanoparticle (NP)-based therapeutics following three diffuse-TBI models: mildclosed-head injury (mCHI), repetitive-mCHI and midline-fluid percussion injury (FPI). We hypothesized that NP accumulation after diffuse TBI correlates directly with blood–brainbarrier permeability. Mice received PEGylated-NP cocktail (20-500 nm) (intravenously) after single- or repetitive-(1 impact/day, 5 consecutive days) CHI (immediately) and midline-FPI (1 h, 3 h and 6 h). NPs circulated for 1 h before perfusion/brain extraction. NP accumulation was analyzed using fluorescent microscopy in brain regions vulnerable to neuropathology. Minimal/no NP accumulation after mCHI/RmCHI was observed. In contrast, midlineFPI resulted in significant peak accumulation of up to 500 nm NP at 3 h post-injury compared to sham, 1 h, and 6 h groups in the cortex. Therefore, our study provides the groundwork for feasibility of NP-delivery based on NPinjection time and NPsize after mCHI/RmCHI and midline-FPI.",
keywords = "Blood-brain barrier, Drug delivery, Fluid percussion injury, Mild closed head injury, Nanoparticles, Optimal therapeutic window, Pharmacodynamics, Traumatic brain injury",
author = "Bharadwaj, {Vimala N.} and Rowe, {Rachel K.} and Jordan Harrison and Chen Wu and Anderson, {Trent R.} and Jonathan Lifshitz and Adelson, {P. David} and Vikram Kodibagkar and Sarah Stabenfeldt",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.nano.2018.06.004",
language = "English (US)",
volume = "14",
pages = "2155--2166",
journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",
issn = "1549-9634",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Blood–brainbarrier disruption dictates nanoparticle accumulation following experimental brain injury

AU - Bharadwaj, Vimala N.

AU - Rowe, Rachel K.

AU - Harrison, Jordan

AU - Wu, Chen

AU - Anderson, Trent R.

AU - Lifshitz, Jonathan

AU - Adelson, P. David

AU - Kodibagkar, Vikram

AU - Stabenfeldt, Sarah

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Clinically, traumatic brain injury (TBI) results in complex heterogeneous pathology that cannot be recapitulated in single pre-clinical animal model. Therefore, we focused on evaluating utility of nanoparticle (NP)-based therapeutics following three diffuse-TBI models: mildclosed-head injury (mCHI), repetitive-mCHI and midline-fluid percussion injury (FPI). We hypothesized that NP accumulation after diffuse TBI correlates directly with blood–brainbarrier permeability. Mice received PEGylated-NP cocktail (20-500 nm) (intravenously) after single- or repetitive-(1 impact/day, 5 consecutive days) CHI (immediately) and midline-FPI (1 h, 3 h and 6 h). NPs circulated for 1 h before perfusion/brain extraction. NP accumulation was analyzed using fluorescent microscopy in brain regions vulnerable to neuropathology. Minimal/no NP accumulation after mCHI/RmCHI was observed. In contrast, midlineFPI resulted in significant peak accumulation of up to 500 nm NP at 3 h post-injury compared to sham, 1 h, and 6 h groups in the cortex. Therefore, our study provides the groundwork for feasibility of NP-delivery based on NPinjection time and NPsize after mCHI/RmCHI and midline-FPI.

AB - Clinically, traumatic brain injury (TBI) results in complex heterogeneous pathology that cannot be recapitulated in single pre-clinical animal model. Therefore, we focused on evaluating utility of nanoparticle (NP)-based therapeutics following three diffuse-TBI models: mildclosed-head injury (mCHI), repetitive-mCHI and midline-fluid percussion injury (FPI). We hypothesized that NP accumulation after diffuse TBI correlates directly with blood–brainbarrier permeability. Mice received PEGylated-NP cocktail (20-500 nm) (intravenously) after single- or repetitive-(1 impact/day, 5 consecutive days) CHI (immediately) and midline-FPI (1 h, 3 h and 6 h). NPs circulated for 1 h before perfusion/brain extraction. NP accumulation was analyzed using fluorescent microscopy in brain regions vulnerable to neuropathology. Minimal/no NP accumulation after mCHI/RmCHI was observed. In contrast, midlineFPI resulted in significant peak accumulation of up to 500 nm NP at 3 h post-injury compared to sham, 1 h, and 6 h groups in the cortex. Therefore, our study provides the groundwork for feasibility of NP-delivery based on NPinjection time and NPsize after mCHI/RmCHI and midline-FPI.

KW - Blood-brain barrier

KW - Drug delivery

KW - Fluid percussion injury

KW - Mild closed head injury

KW - Nanoparticles

KW - Optimal therapeutic window

KW - Pharmacodynamics

KW - Traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=85050717849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050717849&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2018.06.004

DO - 10.1016/j.nano.2018.06.004

M3 - Article

VL - 14

SP - 2155

EP - 2166

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

SN - 1549-9634

IS - 7

ER -